Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novacyt S.A. (FR:ALNOV)
:ALNOV
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 26, 2024
|% Change Since: -30.12%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant achievements such as the resolution of the DHSC dispute and revenue growth, particularly in the cystic fibrosis product. However, these were offset by a substantial loss after tax and increased operating expenses. The company's strong cash position and progress in IVDR certification indicate potential positive future outcomes. Overall, the call reflects a balanced view with both positive strides and notable challenges.Company Guidance
During the call, Novacyt provided several key metrics reflecting their business developments and financial performance. The company reported a revenue increase of over GBP7 million, totaling more than GBP10 million, driven primarily by Yourgene sales post-acquisition. The gross profit was GBP26.5 million with an underlying gross margin of 65% after adjustments. Additionally, the company highlighted a successful resolution of the DHSC dispute, resulting in a net cash inflow of over GBP7 million. Cost-saving initiatives from the integration of Yourgene are projected to deliver GBP5 million in annualized savings by the end of FY '25, achieved 18 months ahead of schedule. The business has a significant cash position of GBP36.5 million as of the end of August, with a focus on sustaining this to reach profitability. Operational highlights included double-digit growth in core products like NIPT and cystic fibrosis testing, with NIPT experiencing a 12% growth and cystic fibrosis over 30%. These efforts are part of Novacyt's strategy to drive organic growth and enhance their product offerings.Successful Resolution of DHSC Dispute
The company resolved the DHSC dispute, resulting in a net cash inflow of over GBP7 million.
Revenue Growth
Revenue increased year-on-year by over GBP7 million to over GBP10 million, driven by the inclusion of Yourgene sales post-acquisition.
Cystic Fibrosis Product Growth
Cystic fibrosis product is the fastest growing in the portfolio with a 30%+ CAGR year-on-year.
Integration Cost Savings
Achieved GBP5 million in cost savings 18 months ahead of schedule through the integration of Yourgene Health.
Strong Cash Position
The company closed the period with just under GBP33 million in the bank, increasing to over GBP36.5 million at the end of August.
IVDR Certification Progress
Cystic fibrosis product has been put through the IVDR process, positioning the company well for regulatory changes.
---
FR:ALNOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FR:ALNOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Sep 26, 2024 | €0.83 | €0.75 | -9.64% |
| May 30, 2024 | €0.76 | €0.67 | -11.68% |
| Sep 28, 2023 | €0.75 | €0.68 | -9.33% |
| Apr 27, 2023 | €0.55 | €0.58 | +4.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novacyt S.A. (FR:ALNOV) report earnings?
Novacyt S.A. (FR:ALNOV) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Novacyt S.A. (FR:ALNOV) earnings time?
Novacyt S.A. (FR:ALNOV) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novacyt S.A. stock?
The P/E ratio of Novacyt is N/A.
What is FR:ALNOV EPS forecast?
Currently, no data Available
---